Open AccessRosuvastatin Lowers Systemic Inflammatory Response in Coronary Artery Bypass Graft Accompanied by Cardiopulmonary Bypass Surgery: A Randomized Controlled Study
Author(s) -
İbrahim Murat Özgüler,
Oktay Burma,
Ayhan Uysal,
Handan Akbulut
Publication year - 2015
Publication title -
clinical and investigative medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.391
H-Index - 47
eISSN - 1488-2353
pISSN - 0147-958X
DOI - 10.25011/cim.v38i4.24260
Subject(s) - medicine , rosuvastatin , cardiopulmonary bypass , anesthesia , systemic inflammatory response syndrome , systemic inflammation , acute coronary syndrome , randomized controlled trial , coronary artery disease , artery , inflammatory response , interleukin 6 , gastroenterology , surgery , cardiology , inflammation , myocardial infarction , sepsis
Cardiopulmonary bypass (CPB) is commonly associated with a systemic inflammatory response that may lead to severe complications. Classic signs of systemic inflammatory response syndrome are complement activation and changes in cytokine and acute phase reactant levels. The effects of rosuvastatin after CPB on interleukin-6 (IL-6), interleukin-10 (IL-10), interleukin-18 (IL-18) and High Sensitivity C-Reactive Protein (hs-CRP) levels were investigated.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom